These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 36743138)
21. Hypofractionated volumetric-modulated arc therapy for breast cancer: A propensity-score-weighted comparison of radiation-related toxicity. Kim N; Chang JS; Shah C; Shin H; Keum KC; Suh CO; Kim YB Int J Cancer; 2021 Jul; 149(1):149-157. PubMed ID: 33600612 [TBL] [Abstract][Full Text] [Related]
22. Gallbladder cancer integrated bioinformatics analysis of protein profile data. Zali MR; Zamanian Azodi M; Razzaghi Z; Heydari MH Gastroenterol Hepatol Bed Bench; 2019; 12(Suppl1):S66-S73. PubMed ID: 32099604 [TBL] [Abstract][Full Text] [Related]
23. Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer. Soni A; Jadhav GK; Manocha S; Chauhan S; Goswami B; Verma M Rep Pract Oncol Radiother; 2022; 27(6):1001-1009. PubMed ID: 36632300 [TBL] [Abstract][Full Text] [Related]
24. EGR1 Is a Critical Gene in Response of Human Keratinocyte to Blue Light Radiation. Hamzeloo-Moghadam M; Rezaei Tavirani M; Razzaghi M; Rezaei Tavirani S; Safari-Alighiarloo N; Arjmand B; Rostami Nejad M J Lasers Med Sci; 2021; 12():e83. PubMed ID: 35155168 [No Abstract] [Full Text] [Related]
25. The long-term outcome of adjuvant hypofractionated radiotherapy and conventional fractionated radiotherapy after breast-conserving surgery for early breast cancer: a prospective analysis of 107 cases. Zhao S; Liu Y; Huang F; Chen X; Cao X; Yu J J Thorac Dis; 2017 Oct; 9(10):3840-3850. PubMed ID: 29268393 [TBL] [Abstract][Full Text] [Related]
26. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116 [TBL] [Abstract][Full Text] [Related]
27. Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics. Wu K; Yin X; Jin Y; Liu F; Gao J Cancer Cell Int; 2019; 19():51. PubMed ID: 30872976 [TBL] [Abstract][Full Text] [Related]
28. The Role of Facility Variation on Racial Disparities in Use of Hypofractionated Whole Breast Radiation Therapy. Laucis AM; Jagsi R; Griffith KA; Dominello MM; Walker EM; Abu-Isa EI; Dilworth JT; Vicini F; Kocheril PG; Browne CH; Mietzel MA; Moran JM; Hayman JA; Pierce LJ; Int J Radiat Oncol Biol Phys; 2020 Aug; 107(5):949-958. PubMed ID: 32376311 [TBL] [Abstract][Full Text] [Related]
29. Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease. Yoon SM; Chu FI; Ruan D; Steinberg ML; Raldow A; Lee P JAMA Netw Open; 2021 Feb; 4(2):e2034074. PubMed ID: 33599771 [TBL] [Abstract][Full Text] [Related]
30. TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas. Wang Y; Cheng T; Lu M; Mu Y; Li B; Li X; Zhan X EPMA J; 2019 Dec; 10(4):395-414. PubMed ID: 31832114 [TBL] [Abstract][Full Text] [Related]
31. Effects of RFRP‑3 on an ovariectomized estrogen‑primed rat model and HEC‑1A human endometrial carcinoma cells. Zhao X; Si L; Niu L; Wei M; Wang F; Liu X; Chen Z; Qiao Y; Cheng L; Yang S Exp Ther Med; 2023 Feb; 25(2):76. PubMed ID: 36684658 [TBL] [Abstract][Full Text] [Related]
32. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N; Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791 [TBL] [Abstract][Full Text] [Related]
33. Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial. Heemsbergen WD; Incrocci L; Pos FJ; Heijmen BJM; Witte MG Front Oncol; 2020; 10():469. PubMed ID: 32346534 [No Abstract] [Full Text] [Related]
38. New biomarkers of Kawasaki disease identified by urine proteomic analysis. Hu HM; Du HW; Cui JW; Feng DQ; Du ZD FEBS Open Bio; 2019 Feb; 9(2):265-275. PubMed ID: 30761252 [TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer. Deshmukh AA; Shirvani SM; Lal L; Swint JM; Cantor SB; Smith BD; Likhacheva A J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059428 [TBL] [Abstract][Full Text] [Related]